Latest disclosed round
Series B
- Date
- 2024-10-01
- Amount
- USD 32.5m
- Sector
- Biotech & techbio
- Companies House
- 10469748
Series B
Enara Bio
Immuno-oncology (TCR-based therapeutics, 'Dark Antigens')
CandidateSeries BOxford
Evidence status
Review retained
- Identity
- Candidate
- Match
- High candidate
- Operating status
- active
- Data origins
- Core directory, Growth Network, Live Chris T D1
Capital network
6 linked investors
Funding record
1 disclosed round
| Date | Stage | Amount | Investors |
|---|---|---|---|
| 2024-10-01 | Series B | $32.5M | Pfizer Ventures, M Ventures, RA Capital, Samsara BioCapital, SV Health Investors, The Francis Crick Institute |
Traceability
Source trail
Funding and investor claims retain their public-source links. This is a research snapshot, not a live cap table.